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Abstract
Background
Trustworthy (i.e. low risk of bias) randomized clinical trials (RCTs) play an important role in
evidence-based decision making. We aimed to systematically assess the risk of bias of trials
published in high-impact endocrinology journals.
Methods
We searched the MEDLINE/PubMed database between 2014 and 2016 for phase 2–4
RCTs evaluating endocrine-related therapies. Reviewers working independently and in
duplicate used the Cochrane Risk of Bias Tool (CCRBT) to determine the extent to which
the methods reported protected the results of each RCT from bias.
Results
We assessed 292 eligible RCTs, of which 40% (116) were judged to be at low risk, 43%
(126) at moderate, and 17% (50) at high risk of bias. Blinding of outcome assessment was
the least common domain reported 43% (125), while selective reporting of outcomes was
the most common 97% (282). In multivariable analysis, RCTs with a parallel design (OR
2.4; 95% CI; 1.2–4.6) and funded by for-profit sources (OR 2.2; 95% CI; 1.3–3.6) were more
likely to be at low risk of bias.
Conclusions
Trustworthy evidence should ultimately shape care to improve the likelihood of desirable
patient outcomes. Six out-of 10 RCTs published in top endocrine journals are at moderate/
high-risk of bias. Improving this should be a priority in endocrine research.
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Introduction
Well conducted randomized clinical trials (RCTs), should help clinicians, patients, and policy-
makers make more confident decisions about care. Attention to this so-called core principle of
evidence-based medicine (EBM),[1] has supported the critical appraisal of the methods used
in RCTs, and has contributed to improve health care.[2–5] Such critical appraisal focuses on
recognizing that RCTs often lack sufficient protection against bias that consequently reduces
the confidence in their estimates.[6, 7] This confidence creates the trustworthiness for clini-
cians to apply evidence into patient care.
Trustworthiness in RCTs can be drawn by assuring the transparency of trial’s methods.[7]
To do so, several strategies have been adopted to guide researchers in their reporting of meth-
ods.[8–11] However, despite these guidance, low quality methodological reporting seems to
prevail among several fields of medicine.[12–15] These untrustworthy studies, which reliability
is at most questionable, are frequently used by policymakers to develop clinical guidelines, pro-
mote an intervention, or generate recommendations often labeled as strong.[16, 17] If patient
care should be stemmed from research evidence that mainly draws its recommendations from
solid evidence aimed at discover, uncover, or invent treatments that improve their lives, rely-
ing in trials in which confidence appear to be obscure by untrustworthy methods opposes the
true essence of EBM.[18] This incongruency of developing guidelines and recommendations
based on quivery evidence, is prone to over- or underestimate the true effect of an interven-
tion, and may ultimately cause harm to the patient or end up being research waste.[19–21] In
this instance, conducting low quality clinical research translates into low quality of evidence
that ultimately causes low quality of care for patients.
The extent to which the results of important RCTs of treatments for endocrine conditions
are protected against bias and thus are trustworthy, however, remains uncertain. Conse-
quently, we aimed to systematically evaluate the overall risk of bias of endocrine RCTs pub-
lished in high-impact journals between 2014–2016.
Material and methods
This systematic review adheres to the Preferred Reporting Items for Systematic Review and
Meta-analysis (PRISMA) (S1 Appendix).[22]
Study eligibility criteria
Eligible articles were phase 2 to 4 RCTs enrolling patients with an endocrinopathy (e.g., diabe-
tes, thyroid, obesity, bone metabolism, cardiovascular (lipids)/metabolism, and pituitary-
gonadal-adrenal axis) to estimate treatment efficacy, regardless of language of publication or
number of participants included in the trial. As our intention was to evaluate potential bias of
RCTs, we decided to only include the first report of the trial and exclude all follow-ups or any
other observational designs (i.e. extensions from an RCTs) aimed at evaluating RCT
population.
Search strategy
With the help of an experienced librarian (N.A-V.), we comprehensively searched MEDLINE/
PubMed using the Cochrane Highly Sensitive Search Strategy[23] for RCTs published between
January 2014 to September 2016—the time frame was chosen arbitrarily—in; a) top five
impact-factor medical journals (New England Journal of Medicine, The Journal of the American
Medical Association [JAMA], Lancet, Annals of Internal Medicine, and the British Medical Jour-
nal [BMJ]), b) two top diabetes journals (Diabetologia and Diabetes Care), c) two top general
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endocrinology journals (Lancet Diabetes & Endocrinology and Journal of Clinical Endocrinol-
ogy and Metabolism [JCEM]), d) two top cardiovascular journals (Journal of the American Col-
lege of Cardiology and Circulation), and e) the five top impact-factor journals of thyroid,
pituitary, bone, and obesity journals (Thyroid, Pituitary, Journal of Bone and Mineral Research,
International Journal of Obesity). All journals were selected based on the 2015 Journal Citation
Reports (JCR) [24]. The complete search strategy is provided in the S2 Appendix.
Selection of studies
Two pairs of reviewers working independently and in duplicate reviewed all potentially eligible
articles. In order to standardize the reviewers’ judgments based on the aforementioned inclu-
sion and exclusion criteria, a pilot study reviewing 20 articles was performed with discussion
until the pairs achieved optimal chance-adjusted inter-reviewer agreement (kappa� 0.8). Dis-
agreements between reviewers were initially resolved by consensus and, when needed, by adju-
dication by an endocrinologist and methodologist (R.R-G. or V.M.M.).
Data collection
Using a standardized web-based form (Online Microsoft Excel 2016, Microsoft, Redmont,
WA, USA), reviewers working independently and in duplicate used the Cochrane Risk of Bias
Tool (CCRBT) to assess the protection against bias afforded by random sequence, allocation
concealment, blinding of personnel and participants, blinding of outcome assessment, incom-
plete outcome data, selective reporting and use of the intention-to-treat analysis.[9] Addition-
ally, we extracted data regarding year of publication, branch of endocrinology, funding,
number of centers, type of outcomes (patient-important outcomes or surrogate or laboratory
outcomes), analysis of data (intention-to-treat or per protocol), and type of journal, interven-
tion, and design.
Risk of bias classification
Each of these seven domains was classified as indicative of high, moderate, or low-risk of bias
based on specific criteria. For instance, we classified random sequence generation as placing a
study at low risk of bias if the method of allocation was explicitly stated in the article (e.g., a
computer-based program was used to randomly allocate patients); when the allocation was
reported only as random, we classified the level of protection against bias as unclear. RCTs
were also considered at low risk of bias when the investigator gathering the data or processing
the data (e.g., trial statistician) were reportedly blind to trial allocation (blinded outcome asses-
sor), when outcomes in trials showed no apparent sign of omission or reporting only positive
outcomes (selective reporting), when loss to follow-up was <20% (incomplete outcome data)
and when analyses adhered to the intention-to-treat principle. A full and detailed description
of each domain is provided in the S1 Table.
When adequate protection was present across all seven domains or if only one domain was
unprotected, we classified the study as at low risk of bias. When>3 domains were classified as
having poor or unclear protections against bias, we classified the study as at high risk of bias.
All other RCTs were classified as at being at moderate risk of bias.
Missing data
When data were missing, unclear or incomplete, we searched for this information in the regis-
tration record of the trial in clinicaltrials.gov, the Australian New Zealand Clinical Trial Regis-
try (ANZCTR), or the University Hospital Medical Information Network Clinical Trial
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Registry (UMIN-CTR). If the study was not registered or data was still unavailable, we con-
tacted the corresponding author. After a lapse of 10 days, if no response was received, we
excluded the article. Every contact was documented and reported. Additionally, we foresighted
that some RCTs would fail to report the study phase. Whenever this happened, we evaluated
each RCT and judged whether it had phase 1 properties, and if so, it was excluded, otherwise
the study was included and labeled as “Not Reported”.
Statistical analysis
We used a descriptive analysis to report categorical variables with frequencies and percentages.
We used multivariable analysis using a logistic regression model to assess the probability of a
study being at low risk of bias (yes/no). Predictors were selected based on previous evidence
and included type of intervention (pharmacological vs. nonpharmacological), trial design (par-
allel vs. other), type of outcome (patient-important outcomes vs. surrogate or laboratory out-
comes), funding (non-profit sources vs. for-profit sources), and number of centers (single vs.
multicenter).[16, 25, 26] Adjustments were made on these same variables and goodness-of-fit
was determined by the c-statistic and Hosmer-Lemeshow test. Additionally, an univariate
analysis was performed to assess the impact of adjusted variables. Trials in which data was
missing, were excluded from the multivariable analysis. All variables were inputted in a step-
wise backward manner and then excluded until a model that best fitted our data was identified.
We took a p value< .05 as statistically significant; associations were described using odds
ratios (ORs) and their associated 95% confidence interval (CI). We used SPSS version 22 (IBM
Corp, Armonk, NY, USA) for all statistical analyses.
Results
We found 292 eligible RCTs (Fig 1). Most RCTs were industry funded (51%), single-center tri-
als (44%) testing a drug vs. placebo (38%) in patients with diabetes (67%) and measuring its
impact on surrogate or laboratory outcomes (70%) (Table 1). A complete list of included arti-
cles is provided as a supplementary file (S2 Table)
Chance-adjusted inter-observer agreement for risk of bias judgments ranged from moder-
ate to acceptable (kappa = 0.5 to 0.8). Of the 292 trials, 116 (40%; 95% CI; 34–45) were judged
to be at low risk, 126 (43%; 95% CI; 37–48) at moderate, and 50 (17%; 95% CI; 13–21%) at
high risk of bias. Blinding of outcomes assessment was the least used protection (43%; 95% CI;
37–49%) and complete reporting the most commonly used protection against bias (97%; 95%
CI; 94–99%) (Table 2). In the multivariable analysis, parallel design (OR 2.4; 95% CI; 1.2–4.6)
and funded by profitable sources (OR 2.1; 95% CI; 1.2–3.6) were associated with better protec-
tion against bias. (Table 3). However, this association was found to be substantially small (R2 =
0.1) and the goodness-of-fit test was moderately inadequate (c-statistic = 0.6 and Hosmer and
Lemeshow = 0.7).
Discussion
Summary of findings
About 4 in 10 endocrine RCTs in top medical journals are adequately protected against bias
and thus warrant high confidence in their estimates. Industry-funded parallel design RCTs
evaluating drugs exhibited the most methodological protections against bias. Fewer than a
third of the reviewed RCTs assessed patient-important outcomes, and almost half of these pro-
duced results judged to be at low-risk of bias.
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Strengths and limitations
To our knowledge, this is the most contemporary analysis evaluating the overall trustworthi-
ness of RCTs in endocrinology. Although a newer version of the CCRBT has recently been
published, perhaps our results may vary with these new rationales for assessing bias in RCTs.
[27] However, because we reviewed only top journals, these results may represent a best-case
scenario, assuming that the peer-review process enriches the published record with more trust-
worthy trials. Conversely, our results may underestimate the protection against bias to the
extent that RCT reports fail to report methods that the investigators did implement.[28] Our
protocol-driven methods and our reliance on multiple, independent, and reproducible judg-
ments to select trials into the review and to analyze each RCT’s risk of bias using a standard-
ized tool should warrant confidence in our findings.
Comparison with previous studies
Several fields of medicine have sought to evaluate the quality of reporting methods in a variety
of fields of medicine.[29–32] Regarding endocrinology, it appears that it has passed more than
20 years and the reporting of methods appears to have barely improve. For instance, in 1996,
Fig 1. Flow diagram of included studies.
https://doi.org/10.1371/journal.pone.0212360.g001
Trustworthiness in endocrine RCT’s
PLOS ONE | https://doi.org/10.1371/journal.pone.0212360 February 19, 2019 5 / 13
Table 1. Risk of bias of the 292 included randomized trials.
Risk of Bias n (%)
Trial Characteristics Total High Moderate Low
All Included Articles 292 50 (17) 126 (43) 116 (40)
Year
2014 119 23 (19) 45 (37) 51 (42)
2015 118 18 (15) 57 (48) 43 (36)
2016 55 9 (16) 24 (43) 22 (40)
Endocrinology Branch
Diabetes 195 (67) 33 (17) 81 (41) 81 (41)
Cardiovascular (Lipids) or Metabolism 42 (14) 3 (7) 22 (52) 17 (40)
Bone 37 (13) 8 (21) 16 (43) 13 (35)
Thyroid 10 (3) 2 (20) 6 (60) 2 (20)
PGA 8 (3) 4 (50) 1 (12) 3 (37)
Type of Intervention
Drug vs.
Placebo 110 (38) 18 (16) 42 (38) 50 (46)
Active Drug 76 (26) 14 (18) 36 (47) 26 (34)
Usual Care 13 (5) 2 (15) 6 (46) 5 (39)
Other 47 (16) 1 (25) 2 (50) 1 (25)
Education or Lifestyle Changes 17 (6) 2 (11) 7 (41) 8 (47)
Nutrition 25 (8.6) 4 (16) 12 (48) 9 (36)
Other Intervention 47 (16) 9 (19) 21 (44) 17 (36)
Type of Journal
Specialty 265 (90) 0 (0) 8 (29.6) 19 (70.4)
General 27 (9) 50 (18.9) 118 (44.5) 97 (36.6)
Phase
2 54 (19) 9 (16) 26 (48) 19 (35)
3 77 (26) 6 (7) 34 (44) 37 (48)
4 47 (16) 5 (10) 22 (46) 20 (42)
Not Reported 114 (39) 30 (26) 44 (38) 40 (35)
Trial Design Cluster 6 1 (16) 2 (33) 3 (50)
Crossover 55 20 (16) 26 (47) 9 (16)
Factorial 3 0 (0) 1 (33) 2 (66)
Parallel 227 29 (12) 97 (42) 101 (44)
Other 1 0 (0) 0 (0) 1 (100)
Number of Centers
Single Center 129 (44) 36 (28) 53 (41) 40 (31)
Few (<10 centers) 56 (19) 7 (13) 25 (45) 24 (43)
Many (>10 centers) 101 (35) 7 (7) 45 (45) 49 (49)
Not Reported 6 (2) 0 (0) 3 (50) 3 (50)
Type of Outcome
Patient-Important Outcomes 89 (31) 7 (7) 40 (44) 42 (47)
Surrogate or Laboratory Outcomes 203 (70) 43 (21) 86 (42) 74 (36)
Type of Analysis
Intention-to-Treat 139 (47) 8 (5) 43 (30) 88 (63)
Per Protocol 153 (52) 42 (28) 83 (54) 28 (18)
Region of Work
Asia 25 1 (4) 17 (68) 7 (28)
(Continued)
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McIver et. al. assessed the quality of methods in 79 trials enrolling patients with type 2 diabetes
and found that the methods used for randomization and blinding were reported in only 15%
and 46%, respectively.[33] Ten years later, Montori et al. evaluated 199 diabetes trials and
judged 53% of these to be at high risk of bias.[26] Although they did not use the CCRBT, that
study also found trials funded by industry to exhibit more protection against bias.[26] More
recently, in 2008, Rios et al. broaden the scope and analyzed 89 trials published in three top
endocrinology journals (e.g. Journal of Clinical Endocrinology and Metabolism [JCEM], Euro-
pean Journal of Endocrinology, and Clinical Endocrinology) and found that the reporting of
allocation concealment (10%), blinding (20%), and intention-to-treat analysis (16%) was sub-
optimal.[34] Although we found an improvement in the reporting of methods, when analyzing
these domains as a whole to determine the overall trustworthiness rendered by trials, we found
that endocrine trials warrant untrustworthy results due to insufficient protection against bias.
This lack of confidence in endocrine trials resonates with what stated by Brito et. al. in their
systematic review, showing that most clinical guidelines recommendations in endocrinology
were supported by evidence warranting low confidence.[35]
Implications for clinical practice and research
For healthcare, to assure that patients receive optimal care that ultimately seeks to improve
their lives, that care must be supported by trustworthy evidence. Clinical recommendations
are a way in which the healthcare enterprise assures that clinicians can make confident deci-
sions regarding patients’ care.[36, 37] Thus, this so called evidence-based practice should be
based on steadfast evidence that warrants confidence and aims at improving patients’ needs
and preferences. Nonetheless, it appears, based on our results, that RCTs are predominantly
being conducted without any proper protection against bias, which consequently causes clini-
cal guidelines to draw recommendations based on estimates warranting low confidence and
directed at improving intangible surrogate markers that render little or no benefit for patients.
[38, 39] These incongruencies in clinical research and practice seems to obviate the main pur-
pose of evidence-based medicine, assuring patient’s wellbeing. In light of this situation, clini-
cians should be more judicious in the confidence inputted in studies or recommendations
they use to provide care.
Table 1. (Continued)
Risk of Bias n (%)
Trial Characteristics Total High Moderate Low
Australia 18 3 (16) 5 (27) 10 (55)
Europe 69 18 (26) 30 (43) 21 (30)
North America 78 20 (25) 30 (38) 28 (35)
South America 3 0 2 (66) 1 (33)
Multicenter 99 8 (8) 42 (42) 49 (49)
Funding
Profit Sources 148 (51) 17 (12) 51 (34) 80 (54)
Non-Profit Sources 109 (37) 22 (20) 57 (52) 30 (28)
Mixed Sources 31 (11) 9 (29) 17 (55) 5 (16)
Not Reported 4 (1) 2 (50) 1 (25) 1 (25)
Data is presented as frequencies (percentages); PGA = pituitary-gonadal-adrenal axis. Low Risk was labeled if seven or six domains were adequately protected. High risk
when three or more domain were inadequately protected against bias. All other instances, were judged as Moderate Risk
https://doi.org/10.1371/journal.pone.0212360.t001
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Table 2. Low risk assessment of the seven domains from the Cochrane Risk of Bias Tool.
Low Risk n (%)
Trials Characteristics Total Random
Sequence
Allocation
Concealment
Blinding of
Personnel and
Participants
Blinding of
Outcome
Assessment
Incomplete
Outcome Data
Selective
Reporting
Intention-
to-Treat
All Included Articles 292 214 (73) 189 (65) 248 (85) 125 (43) 225 (77) 282 (97) 139 (48)
Endocrinology
Branch
Diabetes 195
(67)
142 (66) 124 (65) 168 (67) 70 (56) 159 (70) 189 (67) 108 (77)
Cardiovascular
(Lipids) or
Metabolism
42
(14)
33 (15) 32 (16) 37 (14) 24 (19) 31 (13) 41 (14) 14 (10)
Bone 37
(13)
26 (12) 25 (13) 31 (12) 25 (20) 24 (10) 36 (12) 9 (6)
Thyroid 10 (3) 9 (4) 4 (2) 7 (2) 3 (2) 6 (2) 10 (3) 3 (2)
PGA 8 (3) 4 (1) 4 (2) 5 (2) 3 (2) 5 (2) 6 (2) 5 (3)
Type of
Intervention
Drug vs.
Placebo 110
(378)
81 (37) 76 (40) 103 (41) 54 (43) 84 (37) 105 (37) 48 (34)
Active Drug 76
(26)
53 (24) 45 (23) 59 (23) 24 (19) 59 (26) 74 (26) 42 (30)
Usual Care 13 (5) 10 (4) 8 (4) 10 (4) 5 (4) 12 (5) 12 (4) 5 (3)
Other 47
(16)
3 (1) 3 (1) 3 (1) 2 (1) 3 (1) 4 (1) 0 (0)
Education of
Lifestyle Changes
17 (6) 13 (6) 9 (4) 15 (16) 8 (6) 14 (6) 17 (6) 9 (6)
Nutrition 25 (9) 22 (10) 14 (7) 22 (8) 12 (9) 21 (9) 25 (8) 9 (6)
Other Intervention 47
(16)
32 (15) 34 (18) 36 (14) 20 (16) 32 (14) 45 (16) 26 (18)
Phase
2 54
(19)
35 (16) 33 (17) 46 (18) 21 (16) 45 (20) 54 (19) 30 (21)
3 77
(26)
67 (31) 60 (31) 70 (28) 32 (25) 59 (26) 76 (27) 39 (28)
4 47
(16)
37 (17) 36 (19) 39 (15) 22 (17) 35 (15) 46 (16) 22 (15)
Not Reported 114
(39)
75 (35) 60 (31) 93 (37) 50 (40) 86 (38) 106 (37) 48 (34)
Trial Design
Parallel 227
(77)
175 (81) 161 (85) 193 (77) 108 (86) 173 (76) 221 (78) 115 (82)
Cluster 6 (2) 4 (1) 2 (1) 5 (2) 4 (3) 5 (2) 6 (2) 5 (3)
Crossover 55
(18)
31 (14) 22 (11) 46 (18) 10 (8) 43 (19) 51 (18) 17 (12)
Factorial 3 (1) 3 (1) 3 (1) 3 (1) 2 (1) 3 (1) 3 (1) 2 (2)
Other 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 0 (0)
Type of Journal
General 27 (9) 26 (12) 22 (11) 26 (10) 15 (12) 21 (9) 27 (9) 20 (14)
Specialty 265
(90)
188 (87) 167 (88) 222 (89) 110 (88) 204 (90) 255 (90) 119 (85)
(Continued)
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Furthermore, our findings demonstrate that most investigator initiated RCTs, particularly
those funded by federal agencies and foundations are associated with features that place their
results at high risk of bias. There is evidence that industry funded trials, although more pro-
tected from bias, they are more likely to be affected by spin features—the distortion introduced
by subtle features related to the trial question (e.g., selection of patients, interventions, out-
comes, and methods) and to the presentation of its results—that mislead readers and are
harder to ascertain.[40] Some of these concerns are being addressed by a series of efforts that
include initiatives to promote better standards,[41] prospectively register trials,[42, 43] publish
all the results from all trials,[44] and report trial results in adherence to the Consolidated Stan-
dards of Reporting Trials (CONSORT) reporting statement.[45, 46]. The extent to which these
initiatives are improving the evidence base for endocrine practice appears limited at this point,
Table 2. (Continued)
Low Risk n (%)
Trials Characteristics Total Random
Sequence
Allocation
Concealment
Blinding of
Personnel and
Participants
Blinding of
Outcome
Assessment
Incomplete
Outcome Data
Selective
Reporting
Intention-
to-Treat
Number of
Centers
Single Center 129
(44)
84 (39) 70 (37) 102 (41) 55 (44) 100 (44) 122 (43) 40 (28)
Few (<10 centers) 56
(19)
42 (19) 36 (19) 51 (20) 20 (16) 43 (19) 56 (19) 37 (26)
Many (>10 centers) 101
(35)
82 (38) 78 (41) 89 (35) 47 (37) 76 (33) 99 (35) 60 (43)
Not Reported 6 (2) 6 (2) 5 (2) 6 (2) 3 (2) 6 (2) 5 (1) 2 (1)
Region of Work
Asia 25 (8) 23 (10) 19 (10) 16 (6) 13 (10) 21 (9) 24 (8) 9 (6)
Australia 18 (6) 15 (7) 14 (7) 16 (6) 10 (8) 12 (5) 17 (6) 7 (5)
Europe 69
(23)
46 (21) 36 (19) 58 (23) 20 (16) 50 (22) 65 (23) 29 (20)
North America 78
(26)
47 (22) 42 (22) 66 (26) 35 (28) 62 (27) 76 (27) 33 (23)
South America 3 (1) 3 (1) 3 (1) 3 (1) 1 (1) 3 (1) 3 (1) 0 (0)
Multicenter 99
(33)
80 (37) 75 (39) 89 (35) 46 (36) 77 (34) 97 (34) 61 (43)
Type of
Outcome
Patient-Important
Outcomes
89
(31)
74 (83) 64 (72) 79 (89) 39 (44) 65 (73) 87 (98) 47 (53)
Surrogate or
Laboratory
Outcome
203
(70)
140 (69) 125 (70) 168 (83) 86 (43) 160 (79) 194 (96) 92 (45.3)
Funding
Profit Sources 148
(51)
118 (55) 113 (59) 136 (54) 68 (54) 114 (50) 143 (50) 88 (63)
Non-Profit Sources 109
(39)
76 (35) 62 (32) 87 (35) 48 (38) 85 (37) 106 (37) 37 (26)
Mixed Sources 31
(11)
17 (7) 11 (5) 24 (9) 7 (5) 24 (10) 29 (10) 14 (10)
Not reported 4 (1.4) 3 (1) 3 (1) 1 (1) 2 (1) 2 (1) 4 (1) 0 (0)
Data is presented in frequencies (percentages); PGA = pituitary-gonadal-adrenal.
https://doi.org/10.1371/journal.pone.0212360.t002
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and over the last decade. Even efforts to determine the questions that require better evidence
derived from systematic guideline development appear futile: a systematic survey found that
only 25% of the research gaps identified by The Endocrine Society guideline recommendations
as based on evidence warranting low or very low confidence were being tested in ongoing
RCTs.[47]
Conclusion
Most of the RCTs in endocrinology published in top medical journals seem insufficiently pro-
tected against bias. Improving the methodological quality of RCTs should be a top priority in
endocrine research.
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Funding (Non-profit vs. Profit) 2.39 (1.4–3.9) 2.16 (1.2–3.6)
Center (Single vs. Multicenter) 1.85 (1.1–3) 1.05 (0.5–1.8)
Type of Intervention (No Drug vs Drug) 1.09 (0.6–1.8) 0.67 (0.3–1.2)
Type of Outcome (SorL vs PIO) 1.55 (0.9–2.5) 1.48 (0.8–2.5)
Phase (<4 vs 4) 1.15 (0.6–2.1) 1.2 (0.6–2.3)
Type of Journal (General vs. Specialty) 0.24 (0.1–0.5) 0.29 (0.1–1.7)
SorL = Surrogate or Laboratory Outcomes; PIO = Patient-Important Outcomes
https://doi.org/10.1371/journal.pone.0212360.t003
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